Literature DB >> 16176657

Augmentation of lipopolysaccharide-induced nitric oxide production by alpha-galactosylceramide in mouse peritoneal cells.

Hiroyasu Ito1, Naoki Koide, Akiko Morikawa, Ferdaus Hassan, Shamima Islam, Gantsetseg Tumurkhuu, Isamu Mori, Tomoaki Yoshida, Shinichi Kakumu, Hisataka Moriwaki, Takashi Yokochi.   

Abstract

The effect of alpha-galactosylceramide (alpha-GalCer) on lipopolysaccharide (LPS)-induced nitric oxide (NO) production in mouse peritoneal cells was studied. alpha-GalCer augmented LPS-induced NO production in mouse peritoneal cells, but not in RAW 264.7 macrophage cells. alpha-GalCer augmented NO production, but not tumor necrosis factor (TNF)-alpha production in LPS-stimulated peritoneal cells. Peritoneal cells produced a significant level of interferon (IFN)-gamma in response to alpha-GalCer and anti-IFN-gamma antibody abolished the augmentation of LPS-induced NO production by alpha-GalCer. Moreover, anti-IFN-gamma antibody prevented the enhanced expression of an inducible type of NO synthase mRNA by alpha-GalCer. alpha-GalCer did not augment LPS-induced NO production in peritoneal cells from natural killer T (NKT)-deficient mice. Therefore, it was suggested that alpha-GalCer might augment LPS-induced NO production in peritoneal cells through release of IFN-gamma from NKT cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16176657     DOI: 10.1179/096805105X46628

Source DB:  PubMed          Journal:  J Endotoxin Res        ISSN: 0968-0519


  6 in total

1.  Alpha-galactosylceramide promotes killing of Listeria monocytogenes within the macrophage phagosome through invariant NKT-cell activation.

Authors:  Masashi Emoto; Tomomi Yoshida; Toshio Fukuda; Ikuo Kawamura; Masao Mitsuyama; Eiji Kita; Robert Hurwitz; Stefan H E Kaufmann; Yoshiko Emoto
Journal:  Infect Immun       Date:  2010-03-29       Impact factor: 3.441

2.  Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration.

Authors:  Ryan Gene Soderquist; Evan M Sloane; Lisa C Loram; Jacqueline A Harrison; Ellen C Dengler; Scott M Johnson; Luke D Amer; Courtney S Young; Makenzie T Lewis; Stephen Poole; Matthew G Frank; Linda R Watkins; Erin D Milligan; Melissa J Mahoney
Journal:  Pharm Res       Date:  2010-03-12       Impact factor: 4.200

3.  High susceptibility to lipopolysaccharide-induced lethal shock in encephalomyocarditis virus-infected mice.

Authors:  Hirofumi Ohtaki; Hiroyasu Ito; Masato Hoshi; Yosuke Osawa; Manabu Takamatsu; Akira Hara; Tetsuya Ishikawa; Hisataka Moriwaki; Kuniaki Saito; Mitsuru Seishima
Journal:  Sci Rep       Date:  2012-04-16       Impact factor: 4.379

4.  Toll-like receptor agonists and alpha-galactosylceramide synergistically enhance the production of interferon-gamma in murine splenocytes.

Authors:  Tatsuya Ando; Hiroyasu Ito; Hirofumi Ohtaki; Mitsuru Seishima
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

5.  The equine alveolar macrophage: functional and phenotypic comparisons with peritoneal macrophages.

Authors:  Anna E Karagianni; Ronan Kapetanovic; Bruce C McGorum; David A Hume; Scott R Pirie
Journal:  Vet Immunol Immunopathol       Date:  2013-07-20       Impact factor: 2.046

6.  Inhibition of iNOS activity enhances the anti-tumor effects of alpha-galactosylceramide in established murine cancer model.

Authors:  Hiroyasu Ito; Tatsuya Ando; Mitsuru Seishima
Journal:  Oncotarget       Date:  2015-12-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.